Skip to Main Content

Try STAT+ TODAY

immunotherapy

Most Read

Biotech Matthew Herper

STAT Plus: Lilly’s Retevmo shows success in rare tumors. But can doctors identify the patients who would be helped?

Biotech Shafaq Zia

STAT Plus: Antigen-based metric could better predict which patients benefit from immunotherapy, study says

First Opinion Charles Feng

Oral immunotherapy can be a game changer for many with food allergies

Biotech Kate Sheridan

STAT Plus: Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

Politics Casey Ross

STAT Plus: Medicare proposes a boost in payments for CAR-T and other breakthrough drugs and devices

Health Sharon Begley

STAT Plus: Roche scores first U.S. approval of immunotherapy for breast cancer

First Opinion Neil Canavan

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds

First Opinion Doreen Carvajal

Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope

All Coverage

Health David Steen Martin

‘Colontown’ gives cancer patients an edge in finding new treatments

Lab Chat Megan Thielking

Insight into exhausted immune cells could open new doors for cancer therapy

advertisement

Health Bob Tedeschi

For cancer patients, newest treatments force the ultimate decision, with no room for error

Biotech Damian Garde

Separating hope from hype in the latest cancer treatment ‘revolution’

Biotech Damian Garde

Novel cancer treatment from Kite Pharma notches positive results, but big questions remain

Biotech Sharon Begley

Beware the hype: Top scientists cautious about fighting cancer with immunotherapy

Biotech Meghana Keshavan

Hurdles abound in race to bring customized cancer treatments to masses

Biotech Meghana Keshavan

Experimental cancer therapy holds great promise — but at great cost

Health Rob Waters

Facing bleak odds, cancer patients chase one last chance — in Cuba

In the Lab Sharon Begley

In cancer, it’s back to the future as old treatments make cutting-edge ones more effective

Health Rebecca Robbins

For cancer patients on experimental immunotherapy drugs, it’s been an emotional week

Biotech Damian Garde

FDA lets cancer trial resume after three patient deaths

Biotech Sharon Begley

In Juno patient deaths, echoes seen of earlier failed company

Biotech Damian Garde

After a deadly clinical trial, will immune therapies for cancer be a bust?

Biotech Damian Garde and Meghana Keshavan

Juno halts its immunotherapy trial for cancer after three patient deaths

Business Damian Garde

Pulitzer Prize-winning doctor wades into biotech with cancer startup

Business Sharon Begley

Sean Parker’s put up big bucks for cancer. We’ve got questions